

Chemotherapy Following Radium-223 Dichloride Treatment in ALSYMPCA

Oliver Sartor,^{1,2*} Peter Hoskin,³ Robert E. Coleman,⁴ Sten Nilsson,⁵ Nicholas J. Vogelzang,⁶ Oana Petrenciuc,⁷ Karin Staudacher,⁸ Marcus Thuresson,⁹ and Christopher Parker¹⁰

¹Department of Medicine, Tulane Cancer Center, New Orleans, Louisiana

²Department of Urology, Tulane Cancer Center, New Orleans, Louisiana

³Marie Curie Research Wing for Oncology, Mount Vernon Hospital Cancer Centre, Middlesex, United Kingdom

⁴Academic Unit of Clinical Oncology, Weston Park Hospital, University of Sheffield, Sheffield, United Kingdom

⁵Department of Oncology, Karolinska University Hospital, Stockholm, Sweden

⁶Department of Medical Oncology, University of Nevada School of Medicine and Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada

⁷Department of Global Clinical Development, Bayer HealthCare Pharmaceuticals, Whippany, New Jersey

⁸Department of Study Management Europe, Bayer AS (formerly Algeta ASA), Oslo, Norway

⁹Department of Biostatistics, Statisticon AB, Uppsala, Sweden

¹⁰Academic Urology Unit, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton, Surrey, United Kingdom

BACKGROUND. Radium-223 prolongs overall survival in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases, regardless of prior docetaxel. Whether or not chemotherapy can be safely administered following radium-223 treatment is of clinical importance. An exploratory analysis of prospectively collected data, from the ALSYMPCA (ALpharadin in SYMptomatic Prostate Cancer) patient subgroup who received chemotherapy after radium-223 or placebo treatment, was conducted to evaluate the safety and efficacy of chemotherapy following radium-223.

METHODS. In ALSYMPCA, CRPC patients with symptomatic bone metastases and no visceral metastases were randomized 2:1 to receive six injections of radium-223 (50 kBq/kg IV) or placebo plus best standard of care, stratified by prior docetaxel, baseline alkaline phosphatase, and current bisphosphonate use. In this exploratory analysis, chemotherapy agents administered following study treatment were identified; timing and duration were calculated. Hematologic safety was reviewed, and overall survival analyzed.

RESULTS. Overall, 142 radium-223 and 64 placebo patients received subsequent chemotherapy; most common were docetaxel (70% radium-223, 72% placebo) and mitoxantrone (16% radium-223, 20% placebo). The majority of patients (61% radium-223, 58% placebo) had received prior docetaxel. Radium-223 patients started subsequent chemotherapy later than

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Grant sponsor: Bayer HealthCare Pharmaceuticals.

The copyright line for this article was changed on 15 April 2016 after original online publication.

*Correspondence to: Oliver Sartor, MD, Departments of Medicine and Urology, Box SL-42, Tulane Cancer Center, 1430 Tulane Ave, New Orleans, LA 70112. E-mail: osartor@tulane.edu

Received 5 February 2016; Accepted 1 March 2016

DOI 10.1002/pros.23180

Published online 23 March 2016 in Wiley Online Library

(wileyonlinelibrary.com).

placebo patients; chemotherapy duration was similar between groups. In radium-223 and placebo patients receiving subsequent chemotherapy, median hematologic values (hemoglobin, neutrophils, and platelets) remained nearly constant up to 18 months following start of chemotherapy, regardless of prior docetaxel treatment. A low percentage of patients in both groups had grades 3–4 hematologic values (<10%). Platelet count decline, from last measurement before chemotherapy, was numerically greater in radium-223 versus placebo patients. Median overall survivals from start of chemotherapy were 16.0 and 15.8 months following radium-223 and placebo, respectively.

CONCLUSIONS. Chemotherapy following radium-223, regardless of prior docetaxel, is feasible and appears to be well tolerated in patients with CRPC and symptomatic bone metastases. *Prostate* 76:905–916, 2016.

© 2016 The Authors. *The Prostate* published by Wiley Periodicals, Inc.

KEY WORDS: radium-223; prostate; chemotherapy; safety; alpha emitter; bone

INTRODUCTION

Radium-223 dichloride (radium-223) is a calcium mimetic that specifically targets bone. It decays by emitting high-energy alpha particles that penetrate tissue only to a depth of about 2–10 cell diameters (<100 μM), resulting in highly localized cell killing with minimal damage to surrounding normal tissue including bone marrow cells [1–3]. As a result, radium-223 presents less risk to cells in the bone marrow than external beam radiation therapy (EBRT) and the radiation emitted by other radionuclides used in cancer therapy.

The phase 3 ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) trial with radium-223 in patients with CRPC and symptomatic bone metastases enrolled both patients who had received prior docetaxel and patients who had not [4], unlike other pivotal trials that enrolled docetaxel-naïve or post-docetaxel patients only [5–10]. In ALSYMPCA, radium-223, compared with placebo, prolonged median overall survival (14.9 vs. 11.3 months) and reduced risk of death by 30% (hazard ratio [HR] 0.70; 95%CI: 0.58–0.83; $P < 0.001$), regardless of whether patients had received prior docetaxel (HR 0.70) or not (HR 0.69), establishing the benefits of radium-223 irrespective of prior docetaxel exposure [4,11].

Radium-223 was well tolerated regardless of prior docetaxel exposure, with a low overall incidence of grades 3–4 myelosuppression [11]. Furthermore, preliminary results from an ongoing phase I/IIa study show that a radium-223 plus docetaxel combination therapy is feasible, provided that the docetaxel dose is attenuated and radium-223 is dosed less frequently [12].

The impact of radium-223 on the safety of subsequently administered chemotherapy has not been specifically studied. There has been a reluctance to administer chemotherapy after radioisotope therapy, because of concern that radiation effects in the bone marrow could compromise the safety of chemotherapy [13]. Also, as hematologic parameters often

decline over the course of the disease regardless of therapy, hematologic adverse events (AEs) and bone marrow failure may complicate the clinical course of patients with advanced CRPC [14,15]. An exploratory analysis of prospectively collected data, from the ALSYMPCA patient subgroup who received chemotherapy after completing their assigned study drug treatment, was conducted to evaluate the safety of chemotherapy following radium-223.

METHODS

ALSYMPCA Study Design and Patients

ALSYMPCA was a randomized phase III, double-blind, placebo-controlled trial conducted at 136 centers in 19 countries comparing the efficacy and safety of radium-223 plus best standard of care (BSoC) with placebo plus BSoC in the treatment of patients with CRPC, at least two bone metastases, symptomatic bone disease (either regular analgesic use or treatment with EBRT within the previous 12 weeks, for cancer-related bone pain), and no known visceral metastases [4]. BSoC was defined as the routine care provided at each center (e.g., local EBRT, glucocorticoids, anti-androgens, ketoconazole, or estrogens such as diethylstilbestrol or estramustine). Chemotherapy, hemibody external radiotherapy, and other systemic radionuclides were not permitted during the period from first injection to four weeks after last injection of study drug.

ALSYMPCA eligibility requirements have been published in detail elsewhere [4]. Patients should have received prior docetaxel if available or, if not, were considered either unfit for docetaxel or declined the treatment. The primary end point was overall survival. Safety was assessed on the basis of AEs, hematologic values, clinical laboratory values, and findings on electrocardiography and physical examination. The follow-up period was three years. The study protocol was reviewed and approved by the

institutional review board at each participating center, and all patients provided written informed consent.

Randomization and Masking

In ALSYMPCA, patients were randomized 2:1 to receive six intravenous injections of radium-223 (50 kBq/kg IV) or matching placebo once every four weeks and were stratified by prior docetaxel use (yes vs. no), baseline alkaline phosphatase level (<220 U/L vs. ≥ 220 U/L), and current bisphosphonate use (yes vs. no). Randomization was done with an interactive voice response system, taking into account trial stratification factors. The randomization number was provided to the site investigators, but the assigned treatment was not. Because radium-223 is radioactive, an individual not masked to treatment at each center calculated study drug volume and filled the syringe for masked distribution. All others (patients, investigators, and study funders) were masked to the allocated treatment group.

Patients included in this exploratory analysis were the subgroup of all randomized patients who received subsequent chemotherapy after treatment with radium-223 or placebo. Therefore, the comparability of radium-223 and placebo patients who received subsequent chemotherapy is not assured by the initial randomization of the original study.

Procedures

Chemotherapy was not permitted within the four weeks prior to randomization, during the study treatment period, or within four weeks after the last injection of study drug but was permitted at the investigator's discretion thereafter. During the follow-up period, complete blood counts (CBCs) were conducted at each of nine follow-up visits: one visit every two months for the first six months, and every four months thereafter. CBC schedules had no clear relationship to chemotherapy administered because of varying chemotherapy start times among patients. From 12 weeks after the last study treatment, AEs were recorded only if considered to be related to study drug.

Outcomes—Exploratory Analysis

In this analysis, hematologic safety and overall survival were assessed among patients in the chemotherapy and docetaxel post-study drug subgroups who had previously received radium-223 or placebo. AEs were graded according to the Common Terminology Criteria for Adverse Events (CTCAE). Overall survival was defined as time from start of chemotherapy to date of death.

Statistical Analysis

This exploratory analysis includes prospectively collected data up to the ALSYMPCA study cutoff date of March 2014. Analyses were not powered to assess differences between radium-223 and placebo within the chemotherapy or docetaxel post-study drug subgroups. The chemotherapy post-study drug subgroup included patients who received any chemotherapy following treatment with radium-223 or placebo. The docetaxel post-study drug subgroup included patients who received docetaxel following treatment with radium-223 or placebo (and may have received one or more different types of chemotherapy). Time from randomization to start of chemotherapy, time from end of study treatment to start of chemotherapy, duration of first chemotherapy, and time from first chemotherapy to stop of last chemotherapy (from chemotherapy start to end of treatment or database lock if still on treatment) were calculated using descriptive statistics. CBCs were summarized by 2-month protocol-specified intervals using descriptive statistics. Hazard ratios were calculated using a Cox proportional hazards regression model. Subgroup analyses were performed to assess treatment effects based on prior docetaxel use. Fisher's exact test was used to calculate *P* values for patients with hematologic laboratory values corresponding to grade three or four AEs. Maximum change from baseline in platelets by prior docetaxel use was assessed using the Wilcoxon rank sum test. This trial is registered at ClinicalTrials.gov (NCT00699751).

RESULTS

A total of 921 patients were enrolled in ALSYMPCA between June 2008 and February 2011, 614 in the radium-223 group and 307 in the placebo group (Fig. 1). A total of 407 (66%) radium-223 and 168 (55%) placebo patients entered long-term follow-up. The chemotherapy post-study drug subgroup comprises 206 (22%) patients and includes 142 (23%) patients from the radium-223 group and 64 (21%) patients from the placebo group who received chemotherapy following study treatment (Fig. 1). Demographics and baseline characteristics, including prior docetaxel use and baseline hemoglobin and platelet values, for patients in the chemotherapy post-study drug subgroup were similar between radium-223 and placebo groups. The majority of radium-223 (87 [61%]) and placebo (37 [58%]) patients in the chemotherapy post-study drug subgroup had also received docetaxel prior to study treatment (Table I).

Compared with the entire ALSYMPCA intent-to-treat (ITT) population, the chemotherapy post-study




Fig. 1. Consort diagram. *Safety population includes patients who received at least one injection of study drug. One patient in the placebo group received one injection of radium-223 (week 0) and is included in the radium-223 safety analysis. †Baseline refers to time of last visit prior to start of first post-study chemotherapy. Duration of time in study after start of post-study chemotherapy is defined as time from start of chemotherapy to last registered visit. ‡Percentage of the chemotherapy post-study drug subgroup (142 radium-223, 64 placebo).

drug subgroup were somewhat younger and had less extensive disease (Fig. 1), and a higher percentage of patients in the chemotherapy post-study drug subgroup had received all six injections of study drug (Table II). Within the chemotherapy post-study drug subgroup, more radium-223 patients (79%) received all six injections compared with placebo patients (58%) (Table II), and 79% and 88% of radium-223 and placebo patients, respectively, withdrew early from the study (Fig. 1). Primary reasons for patient withdrawal are listed in Supplementary Table SI.

Chemotherapy Following Study Drug

Docetaxel was the most commonly administered chemotherapy agent, received by 70% (100/142) and 72% (46/64) of radium-223 and placebo patients, respectively. Other commonly administered chemotherapy agents included mitoxantrone (16% [23/142] radium-223, 20% [13/64] placebo), cyclophosphamide (10% [14/142] radium-223, 11% [7/64] placebo), estramustine (4% [6/142] radium-223, 8% [5/64] placebo), and carboplatin (3% [4/142] radium-223, 5% [3/64] placebo). Patients in the chemotherapy post-study drug subgroup may have received one or more

chemotherapy regimens. There was a longer time from randomization to start of chemotherapy for radium-223 (9.1 months) compared with placebo patients (7.5 months). The median time from the last dose of study drug (radium-223 or placebo) to the first dose of chemotherapy was 3.8 months for radium-223 and 2.6 months for placebo. Median duration of first chemotherapy was 4.6 months in the radium-223 group and 4.2 months in the placebo group (Table III).

Hematologic Laboratory Values

Median values for hematologic laboratory parameters (hemoglobin, neutrophils, and platelets) from last measurement before start of chemotherapy (baseline) to 18 months following start of first chemotherapy are shown for both treatment groups in the chemotherapy post-study drug subgroup (Table IV). Although patient dropout rate during this period was high, it was generally balanced between treatment groups (Fig. 1). Median baseline values for neutrophils and platelets were somewhat lower for patients in the radium-223 group than for the placebo group (Table IV). The percentage of patients with hematologic values corresponding to AEs of CTCAE grade 3 or 4 from baseline

TABLE I. Demographics and Baseline Characteristics for Patients in the Chemotherapy Post-Study Drug Subgroup Versus the ALSYMPCA Intent-to-Treat (ITT) Population^a

Characteristic	Chemotherapy post-study drug subgroup		ALSYMPCA ITT population	
	Radium-223 n = 142	Placebo n = 64	Radium-223 N = 614	Placebo N = 307
Median age (range), y	68 (49–85)	68 (50–82)	71 (49–90)	71 (44–94)
Age >75 y, n (%)	20 (14)	12 (19)	171 (28)	90 (29)
Caucasian race, n (%)	133 (94)	60 (94)	575 (94)	290 (95)
Baseline ECOG PS ≤1, n (%)	136 (96)	57 (89)	536 (87)	265 (86)
Extent of disease, n (%)				
<6 metastases	33 (24)	15 (23)	101 (17)	38 (12)
6–20 metastases	60 (43)	34 (53)	258 (42)	146 (48)
>20 metastases	37 (26)	12 (19)	198 (32)	92 (30)
Superscan	10 (7)	3 (5)	54 (9)	30 (10)
WHO ladder for cancer pain, n (%)				
0	0 (0)	0 (0)	12 (2)	2 (1)
1	70 (49)	31 (48)	257 (42)	137 (45)
2	37 (26)	20 (31)	151 (25)	78 (25)
3	35 (25)	13 (20)	194 (32)	90 (29)
Total ALP ≥220 U/L, n (%)	41 (29)	17 (27)	348 (57)	169 (55)
Current bisphosphonate use, n (%)	69 (49)	30 (47)	250 (41)	124 (40)
Prior docetaxel, n (%)	87 (61)	37 (58)	352 (57)	174 (57)
EBRT ≤12 weeks of screening, n (%)	19 (13)	5 (8)	99 (16)	49 (16)
Platelets, median (range) × 10 ⁹ /L ^b	244 (99–560)	251 (108–459)	244 (69–645)	240 (51–580)
Neutrophils, median (range) × 10 ⁹ /L ^b	4.1 (1.7–13.7)	4.1 (2.1–9.7)	4.5 (1.2–17.1)	4.6 (1.4–14.3)
Hemoglobin, median (range), g/dL	12.6 (9.0–15.7)	12.6 (8.7–15.4)	12.2 (8.5–15.7)	12.1 (8.5–16.4)
Albumin, median (range), g/L	40 (24–53)	40.9 (28–49)	40 (24–53)	40 (23–50)
Total ALP, median (range), U/L	119.0 (32.0–2681.0)	139.5 (36.0–2165.6)	211.0 (32–6431)	223.0 (29–4805)
LDH, median (range), U/L	284.0 (135.0–1297.0)	322.5 (132.0–1022.0)	315.5 (108–2171)	335.5 (132–3856)
PSA, median (range), µg/L	85.6 (4.1–848.0)	66.4 (3.6–3457.0)	146.3 (3.8–6026.0)	172.9 (1.5–14500.0)

ALP, alkaline phosphatase; EBRT, external beam radiation therapy; ECOG PS, Eastern Cooperative Oncology Group performance status; LDH, lactate dehydrogenase; PSA, prostate-specific antigen; WHO, World Health Organization.

^aBaseline is defined as the time the patients entered the study.

^bSelected data from the ALSYMPCA safety population.

TABLE II. Extent of Study Drug Exposure for Patients in the Chemotherapy Post-Study Drug Subgroup Versus the ALSYMPCA Intent-to-Treat (ITT) Population

	Chemotherapy post-study drug subgroup		ALSYMPCA ITT population	
	Radium-223 n = 142	Placebo n = 64	Radium-223 N = 614	Placebo N = 307
Number of study injections, median (range)	6 (2–6)	6 (1–6)	6 (0–6)	5 (0–6)
Duration of study treatment, median (range), days	141 (28–177)	141 (1–175)	141 (1–196)	129 (1–190)
Number of study drug injections received, n (%)				
1	0 (0)	3 (5)	18 (3)	21 (7)
2	6 (4)	8 (12)	37 (6)	36 (12)
3	9 (6)	7 (11)	48 (8)	37 (12)
4	9 (6)	3 (5)	60 (10)	34 (11)
5	6 (4)	6 (9)	47 (8)	29 (9)
6	112 (79)	37 (58)	389 (63)	145 (47)

up to 18 months following first post-study drug chemotherapy was generally low (< 10%), but tended to be more common among patients in the radium-223 group (Table V). Grades 3 or 4 hemoglobin, neutrophil, and platelet values were recorded in 8%, 10%, and 6% of radium-223 and 4%, 2%, and 2% of placebo patients, respectively (Table V). No statistically significant differences were found between treatment groups in frequency of hematologic laboratory values corresponding to grade 3 or 4 AEs (Table V). Maximum percentage decreases from baseline in platelets were numerically greater in the radium-223 group than in the placebo group, but did not appear to be associated with prior docetaxel treatment (prior docetaxel: yes, $P=0.400$; no, $P=0.350$) (Fig. 2C and D). Hemoglobin and neutrophils were similar in the two treatment groups, indicating little effect of radium-223 treatment on

hematologic toxicity of subsequent chemotherapy (Fig. 2A and B).

Hematologic laboratory values were also assessed according to docetaxel use prior to enrollment in ALSYMPCA. Among the patients in the chemotherapy post-study drug subgroup, 87/142 (61%) in the radium-223 group and 37/64 (58%) in the placebo group received docetaxel prior to receiving the study drug. Hematologic parameters for patients who received docetaxel prior to radium-223 were similar to those for patients who did not, with no apparent differences between treatment groups up to 18 months (Supplementary Table SII).

Survival

Incidence and cause of death were similar between treatment groups, during and within 30 days of

TABLE III. Timing and Duration of Post-Study Drug Chemotherapy^a

	Radium-223 n = 142	Placebo n = 64
All chemotherapies, n	142	64
Time from randomization to start of chemotherapy, median (range), months	9.1 (1.8–35.6)	7.5 (1.6–26.4)
Time from end of study treatment to start of chemotherapy, median (range), months	3.8 (0–30.4)	2.6 (0.1–20.5)
Duration of first chemotherapy, median (range), months	4.6 (0–59.0)	4.2 (0–60.8)
Time from first chemotherapy to stop of last chemotherapy, median (range), months	6.2 (0–60.9)	8.5 (0–60.8)
Docetaxel, n	100	46
Time from randomization to start of docetaxel, median (range), months	9.2 (1.9–35.6)	7.3 (1.6–24.7)
Time from end of study treatment to start of docetaxel treatment, median (range), months	3.9 (0–30.4)	2.4 (0.1–19.3)
Duration of first docetaxel treatment, median (range), months	5.0 (0–59.0)	4.5 (0–60.8)
Time from first docetaxel treatment to stop of last docetaxel treatment, median (range), months	5.8 (0–60.9)	4.9 (0–60.8)

^aFor some patients with missing treatment end date, duration was calculated from start of treatment (any chemotherapy or docetaxel) until data cutoff date, contributing to long range values.

TABLE IV. Median Hematologic Values for Patients in the Chemotherapy Post-Study Drug Subgroup

Parameter	Radium-223 (n = 142)		Placebo (n = 64)	
	N	Median (range)	N	Median (range)
Hemoglobin, g/dL				
Baseline ^a	142	11.2 (6.4–108.0)	64	11.4 (7.7–15.2)
Month 2	82	10.6 (6.6–14.2)	42	10.8 (7.7–14.2)
Month 4	69	11.0 (6.4–86.0)	25	10.4 (7.1–14.6)
Month 6	50	10.9 (8.5–121.0)	22	10.9 (8.4–14.0)
Month 8	35	10.8 (7.1–12.9)	10	11.1 (9.6–13.1)
Month 10	30	10.8 (7.0–13.6)	17	11.7 (9.2–13.3)
Month 12	28	10.9 (7.8–13.2)	8	10.1 (8.0–13.4)
Month 14	25	11.1 (6.8–13.4)	6	12.0 (11.0–14.0)
Month 16	12	10.8 (8.6–94.0)	3	11.1 (9.3–12.2)
Month 18	17	11.2 (8.9–117.0)	8	10.9 (9.3–13.5)
Neutrophils (absolute) × 10 ⁹ /L				
Baseline ^a	142	3.6 (0.9–26.0)	64	4.5 (1.9–12.5)
Month 2	78	4.4 (0.5–24.4)	38	5.8 (0.5–13.1)
Month 4	66	3.9 (0.1–12.7)	23	5.2 (1.1–12.5)
Month 6	46	4.1 (0.5–16.1)	19	4.8 (1.5–12.2)
Month 8	33	4.1 (1.9–10.7)	9	3.9 (3.0–8.3)
Month 10	27	3.7 (0.2–8.9)	16	4.0 (3.0–8.5)
Month 12	24	4.6 (2.0–8.0)	8	3.6 (2.8–8.9)
Month 14	19	3.6 (0.9–7.4)	5	4.2 (3.1–7.0)
Month 16	11	4.2 (2.9–7.7)	3	4.3 (2.6–7.0)
Month 18	14	3.6 (1.1–8.3)	7	3.8 (2.4–9.2)
Platelets × 10 ⁹ /L				
Baseline ^a	142	215.0 (0.2–782.0)	64	235.5 (48.0–432.0)
Month 2	82	198.5 (0.3–692.0)	42	250.0 (48.0–385.0)
Month 4	69	209.0 (48.0–458.0)	25	220.0 (131.0–411.0)
Month 6	50	215.5 (55.0–494.0)	22	227.0 (99.0–334.0)
Month 8	35	209.0 (0.3–512.0)	10	225.5 (92.0–565.0)
Month 10	29	223.0 (0.2–668.0)	17	239.0 (130.0–512.0)
Month 12	28	215.0 (50.0–464.0)	8	214.5 (89.0–373.0)
Month 14	25	217.0 (26.0–452.0)	6	214.5 (159.0–341.0)
Month 16	12	230.5 (98.0–419.0)	3	314.0 (139.0–326.0)
Month 18	17	246.0 (78.0–601.0)	8	311.0 (143.0–378.0)

^aLast nonmissing measurement prior to start of first post-study drug chemotherapy. Months 2–18 represent 2-month time windows following first date of chemotherapy. Timing of hematology laboratory values is determined according to start of chemotherapy, not by protocol-defined visits.

completing chemotherapy (Table VI). In the radium-223 group, 29% of patients died while receiving chemotherapy, as did a similar proportion of patients in the placebo group (33%). The most common cause of death was prostate cancer-related death in 90% and 95% of patients in the radium-223 and placebo groups, respectively. The proportion of patients who died of nonskeletal metastases was higher in the placebo group (24%) than in the radium-223 group (15%).

Prior treatment with radium-223 did not appear to have a detrimental effect on overall survival with subsequent chemotherapy, when compared with chemotherapy following placebo. Median overall

survival from start of chemotherapy was 16.0 months in patients previously treated with radium-223 and 15.8 months in patients previously treated with placebo.

Docetaxel Following Study Treatment

The most common chemotherapy agent administered following study treatment in ALSYMPCA was docetaxel; therefore, the safety of docetaxel following radium-223 treatment was specifically assessed. Patients in this docetaxel post-study drug subgroup may have also received subsequent chemotherapy with other agents, so data presented here do not

TABLE V. Percentage of Patients With Hematologic Laboratory Values Corresponding to Grades 3 and 4 Adverse Events in the Chemotherapy Post-Study Drug Subgroup

Parameter	Radium-223 (n = 142)		Placebo (n = 64)	
	N	n (%)	N	n (%)
Hemoglobin, <8–6.5 g/dL or <6.5 g/dL				
Baseline ^a	142	4 (3)	64	1 (2)
Month 2	82	5 (6)	42	1 (2)
Month 4	69	3 (4)	25	1 (4)
Month 6	50	0 (0)	22	0 (0)
Month 8	35	1 (3)	10	0 (0)
Month 10	30	2 (7)	17	0 (0)
Month 12	28	1 (4)	8	0 (0)
Month 14	25	2 (8)	6	0 (0)
Month 16	12	0 (0)	3	0 (0)
Month 18	17	0 (0)	8	0 (0)
Total individual patients ^b	116	9 (8)	49	2 (4)
<i>P</i> value ^c				0.509
Neutrophils (absolute) <1–0.5 × 10 ⁹ /L or <0.5 × 10 ⁹ /L				
Baseline ^a	142	1 (1)	64	0 (0)
Month 2	78	5 (6)	38	1 (3)
Month 4	66	2 (3)	23	0 (0)
Month 6	46	1 (2)	19	0 (0)
Month 8	33	0 (0)	9	0 (0)
Month 10	27	2 (7)	16	0 (0)
Month 12	24	0 (0)	8	0 (0)
Month 14	19	1 (5)	5	0 (0)
Month 16	11	0 (0)	3	0 (0)
Month 18	14	0 (0)	7	0 (0)
Total individual patients ^b	114	11 (10)	48	1 (2)
<i>P</i> value ^c				0.112
Platelets <50–25 × 10 ⁹ /L or <25 × 10 ⁹ /L				
Baseline ^a	142	1 (1)	64	1 (2)
Month 2	82	4 (5)	42	1 (2)
Month 4	69	1 (1)	25	0 (0)
Month 6	50	0 (0)	22	0 (0)
Month 8	35	2 (6)	10	0 (0)
Month 10	29	1 (3)	17	0 (0)
Month 12	28	0 (0)	8	0 (0)
Month 14	25	1 (4)	6	0 (0)
Month 16	12	0 (0)	3	0 (0)
Month 18	17	0 (0)	8	0 (0)
Total individual patients ^b	116	7 (6)	49	1 (2)
<i>P</i> value ^c				0.438

^aLast nonmissing measurement prior to start of first post-study drug chemotherapy. Months 2–18 represent 2-month time windows following first date of chemotherapy. Timing of hematology laboratory values is determined according to start of chemotherapy, not by protocol-defined visits.

^bTotal individual patients with any post-baseline laboratory measurement.

^c*P* values reflect data in the row above (total individual patients with post-baseline laboratory measurement).

reflect a pure population of patients treated with docetaxel alone.

Demographics and baseline characteristics, study drug exposure, and disposition were similar to those in the chemotherapy post-study drug subgroup (Supplementary Tables SIII–SV). Consistent with the che-

motherapy post-study drug subgroup, there was a longer time from randomization to start of docetaxel for patients in the radium-223 group (9.2 months) compared with the placebo group (7.3 months). The median time from the last dose of study drug to the first dose of docetaxel was 3.9 months for the radium-




Fig. 2. Maximum percentage decrease from baseline values for hemoglobin (A), neutrophils (B), platelets (C), and platelets by prior docetaxel treatment (D).

TABLE VI. Deaths During or Within 30 Days of Completing Chemotherapy in the Chemotherapy Post-Study Drug Subgroup

	Radium-223 n = 142	Placebo n = 64
Number (%) of deaths while still on chemotherapy	41 (29)	21 (33)
Prostate cancer-related death, n (%)	37 (90)	20 (95)
Skeletal metastases	31 (76)	15 (71)
Other metastases	6 (15)	5 (24)
Non-prostate cancer-related death, n (%)	4 (10)	1 (5)
Bronchopneumonia	1 (2)	0 (0)
Cardiopulmonary failure	0 (0)	1 (5)
Cerebral hemorrhage	1 (2)	0 (0)
Respiratory failure	1 (2)	0 (0)
Sepsis	1 (2)	0 (0)

223 group and 2.4 months for the placebo group. The median duration of first docetaxel therapy was 5.0 months in the radium-223 group and 4.5 months in the placebo group (Table III).

Hematologic assessments for patients with docetaxel following study treatment were consistent with the overall chemotherapy post-study drug subgroup. Median hematologic values remained generally constant over time, regardless of prior docetaxel exposure (Supplementary Tables SVI and SVII). Maximum percentage decreases from baseline in hemoglobin and neutrophils were similar between radium-223 and placebo patients (Supplementary Fig. S1A and B). The maximum percentage decrease in platelet counts was somewhat greater in radium-223 patients, consistent with the entire chemotherapy post-study drug subgroup, and did not appear to be associated with prior docetaxel treatment (prior docetaxel: yes, $P = 0.279$; no $P = 0.197$) (Supplementary Fig. S1C and D). The decrease in platelets in this subgroup and in the overall chemotherapy post-study drug subgroup was likely a consequence of radium-223 treatment, rather than of docetaxel following radium-223, as a higher incidence of grades 3–4 thrombocytopenia (although in <10% of patients) was reported with radium-223 versus placebo in ALSYMPCA [4].

For the docetaxel post-study drug subgroup, median overall survival from start of docetaxel was 17.5 and 16.7 months in patients previously treated with radium-223 or placebo, respectively. Prostate cancer-related death remained the most common cause of death in both treatment groups (Supplementary Table SVIII).

DISCUSSION

In this exploratory analysis, no safety concerns were identified with chemotherapy following ra-

dium-223, and no detrimental effects on overall survival were observed. These findings represent an initial step in defining how radium-223 affects the safety of subsequent chemotherapy, an issue that will be further addressed as radium-223 is used earlier in the treatment of patients with CRPC [16].

Of note, among the 142 radium-223 patients who received subsequent chemotherapy, most (79%) had received all six planned radium-223 doses, which is the recommended regimen in the product label and as used in the ALSYMPCA trial. Interestingly, a substantial proportion (61%) of patients received docetaxel before radium-223 and received subsequent chemotherapy following radium-223 treatment; 39% of patients who received chemotherapy following radium-223 were chemotherapy naïve. Data presented here indicate that the use of chemotherapy following radium-223 is feasible regardless of prior docetaxel use.

Several limitations of this exploratory analysis need to be considered in interpreting its findings regarding broader questions of treatment sequencing. The chemotherapy post-study drug subgroup of ALSYMPCA may have been affected by post-randomization factors; therefore, the comparability of radium-223 and placebo patients who received subsequent chemotherapy is not assured by the initial randomization of the original study. Hematologic data used in the exploratory analysis were recorded at intervals specified by the ALSYMPCA follow-up schedule, rather than as time points determined for the optimal assessment of the hematologic toxicity related to chemotherapy. Consequently, sample collections may not have coincided with the expected nadirs in hemoglobin, neutrophil, and platelet counts. In addition, the median values reported may obscure a small number of patients who may have had severe but transient myelosuppression following chemotherapy. Data for

precise dosing and intervals of the chemotherapy regimens were not collected. Because of a high patient dropout rate during the follow-up period, the analysis was not designed with the statistical power to fully assess hematologic safety between radium-223 and placebo in the chemotherapy post-study drug subgroup. The safe use of other agents following treatment with radium-223 remains to be studied. Agents with potential myelosuppressive effects include cabazitaxel, and poly(ADP-ribose) polymerase inhibitors such as olaparib.

Radium-223 significantly prolonged median overall survival compared with placebo, irrespective of prior treatment with docetaxel (prior docetaxel: HR 0.70; 95%CI: 0.56–0.88; $P=0.002$; no prior docetaxel: HR 0.69; 95%CI: 0.52–0.92; $P=0.01$) [11]. The ALSYMPCA trial also showed that patients who received prior docetaxel had more hematologic toxicity than those who were docetaxel naïve, although the incidence of grade three or four thrombocytopenia was less than 10% in both groups [4,11]. The data in the present safety analysis in the chemotherapy post-study drug subgroup suggest that chemotherapy may be safely given after radium-223, an important finding especially if radium-223 is to be considered earlier in the course of the disease. Additionally, survival with chemotherapy was similar between treatment groups, suggesting that prior treatment with radium-223 did not compromise the efficacy of subsequent chemotherapy. At this time, although we know from ALSYMPCA that radium-223 can be safely administered before or after docetaxel, and that docetaxel may be safely administered before radium-223 [11], we support the concept of prospective studies to fully understand the efficacy and safety of chemotherapy following radium-223 treatment.

CONCLUSION

This exploratory analysis of ALSYMPCA data represents the first and only evaluation of the safety of chemotherapy following radium-223 treatment, and identifies no significant safety concerns; thus, the use of chemotherapy after radium-223 is not contraindicated.

FINANCIAL DISCLOSURES

OS reports grants and personal fees from Bayer and Bayer AS (formerly Algeta ASA) during the conduct of the study. PH has nothing to disclose. REC reports personal fees for expert testimony from Novartis. SN reports an advisory relationship with Bayer. NJV reports a consultancy relationship with Bayer, outside the submitted work. OP reports em-

ployment with Bayer HealthCare. KS reports employment with Bayer AS (formerly Algeta ASA). MT reports a statistical consultancy relationship with Bayer HealthCare, during the conduct of the study and outside the submitted work. CP reports grants and personal fees from Bayer and personal fees from Janssen, BNIT, Sanofi-Aventis, and Takeda, outside the submitted work.

ACKNOWLEDGMENTS

All authors had full access to the data and participated in the development and review of the manuscript. Manuscript writing assistance was provided by Joanna K. Sandilos Rega, PhD, of SciStrategy Communications (West Conshohocken, PA), funded by Bayer HealthCare Pharmaceuticals.

REFERENCES

1. Bruland OS, Nilsson S, Fisher DR, Larsen RH. High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter ²²³Ra: Adjuvant or alternative to conventional modalities? *Clin Cancer Res* 2006;12:6250s–6257s.
2. Henriksen G, Bristol K, Bruland OS, Fodstad O, Larsen RH. Significant antitumor effect from bone-seeking, alpha-particle-emitting (²²³Ra) demonstrated in an experimental skeletal metastases model. *Cancer Res* 2002;62:3120–3125.
3. Henriksen G, Fisher DR, Roeske JC, Bruland OS, Larsen RH. Targeting of osseous sites with alpha-emitting ²²³Ra: Comparison with the beta-emitter ⁸⁹Sr in mice. *J Nucl Med* 2003;44:252–259.
4. Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fossa SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall'Oglio M, Franzen L, Coleman R, Vogelzang NJ, O'Bryan-Tear CG, Staudacher K, Garcia-Vargas J, Shan M, Bruland OS, Sartor O, Investigators A. Alpha emitter radium-223 and survival in metastatic prostate cancer. *N Engl J Med* 2013;369:213–223.
5. Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. *N Engl J Med* 2004;351:1513–1520.
6. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA, Investigators TAX. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. *N Engl J Med* 2004;351:1502–1512.
7. Ryan C, Smith M, de Bono J, Molina A, Logothetis C, de Souza P, Fizazi K, Mainwaring P, Piulats J, Siobhan N, Carles J, Mulders P, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee S, Suttman H, Gerristen W, Flaig T, George D, Yu E, Efsthathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE. Abiraterone in metastatic prostate cancer without previous chemotherapy. *N Engl J Med* 2013;368:1458–1459.

8. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF, Investigators IS. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. *N Engl J Med* 2010;363:411–422.
9. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B. Enzalutamide in metastatic prostate cancer before chemotherapy. *N Engl J Med* 2014;371:424–433.
10. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Flechon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS. Increased survival with enzalutamide in prostate cancer after chemotherapy. *N Engl J Med* 2012;367:1187–1197.
11. Hoskin P, Sartor O, O'Sullivan JM, Johannessen DC, Helle SI, Logue J, Bottomley D, Nilsson S, Vogelzang NJ, Fang F, Wahba M, Aksnes AK, Parker C. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: A prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. *Lancet Oncol* 2014;15:1397–1406.
12. Morris MJ, Higano CS, Scher HI, Sweeney C, Antonarakis ES, Shevrin DH, Ryan C, Loriot Y, Fizazi K, Pandit-Taskar N, Garcia-Vargas J, Lyseng K, Bloma M, Aksnes AK, Carrasquillo J. Safety of radium-223 dichloride with docetaxel in patients with bone metastases from castration-resistant prostate cancer: A phase 1/2a clinical trial. *Ann Oncol* 2014;25(Suppl 4):iv261. Abstr 765PD.
13. Kellokumpu-Lehtinen PL, Hjalms-Eriksson M, Thellenberg-Karlsson C, Astrom L, Franzen L, Marttila T, Seke M, Taalikka M, Ginman C. Toxicity in patients receiving adjuvant docetaxel+hormonal treatment after radical radiotherapy for intermediate or high-risk prostate cancer: A preplanned safety report of the SPCG-13 trial. *Prostate Cancer Prostatic Dis* 2012;15:303–307.
14. Nalesnik J, Mysliwiec A, Canby-Hagino E. Anemia in men with advanced prostate cancer: Incidence, etiology, and treatment. *Rev Urol* 2004;6:1–4.
15. Nieder C, Haukland E, Pawinski A, Dalhaug A. Anaemia and thrombocytopenia in patients with prostate cancer and bone metastases. *BMC Cancer* 2010;10:284.
16. Smith M, Parker C, Tombal B, Miller K, Saad F, Fang F, Zhang A, Kornacker M, Higano CS. ERA223: A phase 3 trial of radium-223 dichloride in combination with abiraterone acetate and prednisone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naive patients with bone predominant metastatic castration-resistant prostate cancer. *J Clin Oncol* 2015;33: Abstr TPS5082.

SUPPORTING INFORMATION

Additional supporting information may be found in the online version of this article at the publisher's web-site.